Tag Archives: Federal Circuit

Novartis Wins Landmark Biosimilar Approval

Novartis Navigates The FDA-ACA Maze – Gets Approval For Generic Neuprogen. Amgen will soon find itself in a price war with Sandoz – a Novartis company – as it tries to maintain its share of the market for Neuprogen (filgraslim). … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

Pacing Technologies v. Garmin – D&D Explained

In this decision—No. 2014-1396 (Fed. Cir., Feb. 18, 2015)—the court affirmed a grant of summary judgment (a copy can be found at the end of this post) that Garmin’s exercise products do not infringe the claims of Pacing’s US Pat. … Continue reading

Posted in Claim Interpretation, Patent Eligible Subject Matter | Tagged , , , , | Leave a comment

“Precision Medicine” Initiative Leaves Patents “Lost in Space”

On January 30th, the White House released a press release expanding upon President Obama’s mention of “precision medicine” in his State of the Union Address. Not surprisingly, the details are pretty much what we who are involved in various aspects … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , | Leave a comment

TEVA v. SANDOZ – THE DISSENT AND THE ZONE OF UNCERTAINTY

In Teva v. Sandoz, decided yesterday by a 7-2 decision of the S. Ct., the lengthy dissent by Justices Alito and Thomas invoked the dreaded “zone of uncertainty” – a dangerous bar of shifting legal sands that defendants should not … Continue reading

Posted in Claim Interpretation | Tagged , , , , , , , , | Leave a comment